<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112108</article-id><article-id pub-id-type="publisher-id">ACM-40723</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_63965585.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  术前炎性指标评估喉癌复发的临床意义
  The Clinical Significance of Preoperative Inflammatory Indexes in Evaluating the Recurrence of Laryngeal Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>艳珍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>得力</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>修凯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>755</fpage><lpage>762</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨术前中性粒细胞、淋巴细胞、单核细胞、血小板、中性粒细胞淋巴细胞比率(NLR)、血小板淋巴细胞比率(PLR)、淋巴细胞单核细胞比率(LMR)与喉鳞状细胞癌复发的关联及临床意义。方法：对在青岛大附属医院初次手术治疗的196例喉鳞状细胞癌患者进行回顾性研究，收集符合标准患者的临床数据及炎性指标数据，炎性指标数据用均数 &#177; 标准差(x &#177; s)表示，采用t检验和单因素方差分析或者Mann-Whitney U秩和检验和Kruskal-Wallis检验分析炎性指标与喉癌复发的关联。结果：单一性炎性指标中，仅淋巴细胞与喉癌的复发存在统计学意义(P &lt; 0.01)，在复合性炎症指标中，NLR、PLR、LMR都是显著影响喉癌复发的因素(P &lt; 0.01)。淋巴结转移、T分期越大、临床分期越晚，NLR和PLR则越高，而LMR越低。结论：术前NLR、PLR升高以及淋巴细胞、LMR降低可用于预测喉癌的复发。
    Objective: To investigate the correlation and clinical significance of preoperative neutrophils, lymphocytes, monocytes, platelets, neutrophilto lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and recurrence of laryngeal squamous cell carcinoma (LSCC). Methods: A retrospective study was conducted on 196 patients with laryngeal squamous cell carcinoma who were treated for the first time in Qingdao University Hospital. The clinical data and inflammatory index data of patients meeting the standards were collected. The inflammatory index data was used as mean &#177; standard deviation (x &#177; s) means that the t-test and one-way analysis of variance or Mann-Whitney U rank sum test and Kruskal-Wallis test are used to analyze the association between inflammatory indicators and the recurrence of laryngeal cancer. Results: Among the single inflammatory indexes, only the recurrence of lymphocytes and laryngeal cancer was statistically significant (P &lt; 0.01). Among the complex inflammatory indexes, NLR, PLR, and LMR were all significant factors affecting the recurrence of laryngeal cancer (P &lt; 0.01). Lymph node metastasis, the larger the T stage, the later the clinical stage, result of the higher the NLR and PLR, and the lower the LMR. Conclusion: Preoperative increase in NLR or PLR and decrease in lymphocytes or LMR can be used to predict the recurrence of laryngeal cancer. 
  
 
</p></abstract><kwd-group><kwd>喉癌，中性粒细胞淋巴细胞比率，血小板淋巴细胞比率，淋巴细胞单核细胞比率，复发, Laryngeal Cancer</kwd><kwd> Neutrophil to Lymphocyte Ratio</kwd><kwd> Platelet to Lymphocyte Ratio</kwd><kwd> Lymphocyte to Monocyte Ratio</kwd><kwd> Recurrence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨术前中性粒细胞、淋巴细胞、单核细胞、血小板、中性粒细胞淋巴细胞比率(NLR)、血小板淋巴细胞比率(PLR)、淋巴细胞单核细胞比率(LMR)与喉鳞状细胞癌复发的关联及临床意义。方法：对在青岛大附属医院初次手术治疗的196例喉鳞状细胞癌患者进行回顾性研究，收集符合标准患者的临床数据及炎性指标数据，炎性指标数据用均数 &#177; 标准差(x &#177; s)表示，采用t检验和单因素方差分析或者Mann-Whitney U秩和检验和Kruskal-Wallis检验分析炎性指标与喉癌复发的关联。结果：单一性炎性指标中，仅淋巴细胞与喉癌的复发存在统计学意义(P &lt; 0.01)，在复合性炎症指标中，NLR、PLR、LMR都是显著影响喉癌复发的因素(P &lt; 0.01)。淋巴结转移、T分期越大、临床分期越晚，NLR和PLR则越高，而LMR越低。结论：术前NLR、PLR升高以及淋巴细胞、LMR降低可用于预测喉癌的复发。</p></sec><sec id="s2"><title>关键词</title><p>喉癌，中性粒细胞淋巴细胞比率，血小板淋巴细胞比率，淋巴细胞单核细胞比率，复发</p></sec><sec id="s3"><title>The Clinical Significance of Preoperative Inflammatory Indexes in Evaluating the Recurrence of Laryngeal Carcinoma<sup> </sup></title><p>Yanzhen Tang<sup>*</sup>, Deli Wang, Xiukai Zhao, Jie Qiu<sup>#</sup></p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/47-1571950x4_hanspub.png" /></p><p>Received: Jan. 23<sup>rd</sup>, 2021; accepted: Feb. 7<sup>th</sup>, 2021; published: Feb. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/47-1571950x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the correlation and clinical significance of preoperative neutrophils, lymphocytes, monocytes, platelets, neutrophilto lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and recurrence of laryngeal squamous cell carcinoma (LSCC). Methods: A retrospective study was conducted on 196 patients with laryngeal squamous cell carcinoma who were treated for the first time in Qingdao University Hospital. The clinical data and inflammatory index data of patients meeting the standards were collected. The inflammatory index data was used as mean &#177; standard deviation (x &#177; s) means that the t-test and one-way analysis of variance or Mann-Whitney U rank sum test and Kruskal-Wallis test are used to analyze the association between inflammatory indicators and the recurrence of laryngeal cancer. Results: Among the single inflammatory indexes, only the recurrence of lymphocytes and laryngeal cancer was statistically significant (P &lt; 0.01). Among the complex inflammatory indexes, NLR, PLR, and LMR were all significant factors affecting the recurrence of laryngeal cancer (P &lt; 0.01). Lymph node metastasis, the larger the T stage, the later the clinical stage, result of the higher the NLR and PLR, and the lower the LMR. Conclusion: Preoperative increase in NLR or PLR and decrease in lymphocytes or LMR can be used to predict the recurrence of laryngeal cancer.</p><p>Keywords:Laryngeal Cancer, Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, Recurrence</p><disp-formula id="hanspub.40723-formula69"><graphic xlink:href="//html.hanspub.org/file/47-1571950x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/47-1571950x8_hanspub.png" /> <img src="//html.hanspub.org/file/47-1571950x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>喉癌是头颈部常见的恶性肿瘤之一，全世界每年约有177,000例新发喉癌病例，死亡病例约有94,000例。基于2014年喉癌全国肿瘤登记中心收集喉癌资料分析得出，我国喉癌发病世标率为1.14/10万，喉癌死亡世标率为0.60/10万，是头颈部恶性肿瘤发病的第2位，在耳鼻咽喉头颈外科恶性肿瘤中占7.3%~35% [<xref ref-type="bibr" rid="hanspub.40723-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref3">3</xref>]。因喉部器官的特殊性，喉癌在治疗上注重生存率与生活质量并重的治疗方式。随着手术、放化疗等多种治疗方式的发展，早期喉癌患者(I期和II期患者)的5年疾病生存率较高，但晚期喉癌患者(III期和IV期患者) 5年疾病生存率低，研究显示晚期患者生存率低与肿瘤转移和复发有很大关联。尽管治疗手段和技术不断进步，但近十年来，喉癌的生存率没有进一步升高，反而出现了下降。进一步的研究影响预后的因素对改善患者预后有着积极的作用。随着人们对肿瘤发生发展机制研究的逐步深入，发现炎症不仅对机体产生保护作用，过度的不可控的炎症反应，可通过改变细胞生存微环境而促进癌细胞的发生、发展及转移 [<xref ref-type="bibr" rid="hanspub.40723-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref5">5</xref>]。非可控性炎症被发现参与多种癌症发生的起始阶段，研究机体炎症、免疫等微环境的改变，进一步明确炎症与肿瘤发生发展的机制，是实现癌症早防、早诊、早治的一个突破口。越来越多的研究显示机体炎性反应能预测癌症患者的预后，单一的炎症指标如中性粒细胞、淋巴细胞、血小板等，联合性炎性指标有中性粒细胞淋巴细胞比率(neutrophil to lymphocyte ratio, NLR)、血小板淋巴细胞比率(platelet to lymphocyte ratio, PLR)、淋巴细胞单核细胞比率(lymphocyte to monocyte ratio, LMR)和格拉斯哥预后评分/改良格拉斯哥预后评分(GPS/MGPS)等，它们被证实与多种癌症的总生存率、疾病无进展生存率(DFS)显著相关 [<xref ref-type="bibr" rid="hanspub.40723-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref7">7</xref>]。但炎症指标与喉癌复发的关系较少被研究。本文主要研究了中性粒细胞、淋巴细胞、单核细胞、NLR、PLR、LMR等炎性指标与喉癌复发间的关联。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>这是一项回顾性研究，研究对象为2014年1月至2018年12月期间在青岛大学附属医院耳鼻咽喉头颈外科就诊的喉鳞状细胞癌患者，患者纳入标准：病理组织学活检确诊为喉鳞状细胞癌；初始治疗方式为手术治疗；具有完整的病历资料。排除标准：患者既往有其他部位癌症病史；手术治疗前做过化疗、放疗等其他治疗；有可能影响机体产生炎症反应的基础疾病：如自身免疫性疾病、急性感染性疾病、血液系统疾病、激素治疗史或慢性肾功能不全的患者；合并心肺严重疾病的患者。收集符合标准患者的临床数据及炎性指标数据，喉癌分期以AJCC第八版为参考标准 [<xref ref-type="bibr" rid="hanspub.40723-ref8">8</xref>]。患者的临床数据包括性别、年龄、吸烟史、饮酒史、病理分化、肿瘤部位、T分期、淋巴结转移、临床分期。患者的炎性指标数据包括术前5天内的中性粒细胞、淋巴细胞、单核细胞、血小板、NLR、PLR、LMR。通过对患者所有住院及门诊病历资料的查阅，并通过电话随访了解患者病情变化，以喉癌复发为研究终点，随访最长时限为5年。本研究经医院伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. 统计学方法</title><p>选择SPSS26.0统计软件进行数据分析，计量资料用均数 &#177; 标准差(x &#177; s)表示，采用K-S检验样本的正态性。正态分布数据，组间比较采用t检验或者单因素方差分析。非正态分布数据，组间比较采用Mann-Whitney U秩和检验或者Kruskal-Wallis检验。当P &lt; 0.05被认为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床资料</title><p>2014年1月~2018年12月在青岛大附属医院耳鼻咽喉科行初次手术治疗的196例喉鳞状细胞癌患者符合上述标准。其中复发67例(34.18%)，未复发129例(65.82%)；男188例(95.92%)，女8例(4.08%)；年龄 &lt; 60岁50例(25.51%)，≥60岁146例(74.49%)；吸烟174例(88.78%)，未吸烟22例(11.22%)；饮酒137例(69.90%)，未饮酒59例(30.10%)；声门型喉癌患者132例(67.35%)，声门上型喉癌患者42例(21.43%)，声门下型喉癌患者8例(4.08%)，全声门型喉癌患者14例(7.14%)；早期(I~II期)患者129例(65.82%)，晚期(III~IV期)患者67例(34.18)；高分化92例(46.94%)，中分化76例(38.78%)，低分化28例(14.28%)；N<sub>0</sub> (无淋巴结转移) 39例(19.9%)、N<sub>X</sub> (有淋巴结转移) 157例(80.1%)。所有淋巴结阳性患者均行术后放射治疗。</p></sec><sec id="s7_2"><title>3.2. 炎性指标与喉癌复发之间的关联</title><p>在单一性炎性指标中，仅淋巴细胞与喉癌的复发存在统计学意义(P &lt; 0.01)。在复合性炎症指标中，NLR、PLR、LMR都是显著影响喉癌复发的因素(P &lt; 0.01)。如表1所示，复发组NLR及PLR均值较未复发组高，而复发组淋巴细胞及LMR均值较未复发组低。提示NLR及PLR的升高、淋巴细胞及LMR降低与喉癌复发存在关联。</p></sec><sec id="s7_3"><title>3.3. 炎性指标与临床特征的关联</title><p>在单一性炎性指标中，年龄、饮酒史、病理分化、肿瘤部位、T分期、淋巴结转移、临床分期与各炎性指标间无统计学差异，如表2所示。有吸烟史者淋巴细胞均值较未吸烟史者高，吸烟与淋巴细胞数值存在统计学差异(P &lt; 0.05)。在复合性炎症指标中，如表3所示，NLR、PLR在肿瘤临床分期、T分期、淋巴结转移上存在统计学差异(P &lt; 0.05)，在性别、年龄、吸烟、饮酒、肿瘤部位上无明显统计学差异(P &gt; 0.05)。而LMR在性别、分化程度及淋巴结转移上存在统计学意义，在其他临床特征上无明显统计学差异。上述结果提示淋巴结转移、T分期越大、临床分期越晚，NLR和PLR则越高，而LMR越低。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Correlation between preoperative inflammatory index and recurrence of laryngeal cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >指标</th><th align="center" valign="middle"  colspan="2"  >复发</th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >白细胞(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >7.03 &#177; 1.55</td><td align="center" valign="middle" >6.74 &#177; 2.06</td><td align="center" valign="middle" >0.550</td></tr><tr><td align="center" valign="middle" >中性粒细胞(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >4.58 &#177; 1.15</td><td align="center" valign="middle" >3.89 &#177; 1.45</td><td align="center" valign="middle" >0.05</td></tr><tr><td align="center" valign="middle" >淋巴细胞(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >1.79 &#177; 0.28</td><td align="center" valign="middle" >2.10 &#177; 0.53</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >单核细胞(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.49 &#177; 0.13</td><td align="center" valign="middle" >0.45 &#177; 0.14</td><td align="center" valign="middle" >0.296</td></tr><tr><td align="center" valign="middle" >血小板(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >220.13 &#177; 31.01</td><td align="center" valign="middle" >217.54 &#177; 36.08</td><td align="center" valign="middle" >0.767</td></tr><tr><td align="center" valign="middle" >NLR</td><td align="center" valign="middle" >2.58 &#177; 0.70</td><td align="center" valign="middle" >1.88 &#177; 0.56</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >PLR</td><td align="center" valign="middle" >124.82 &#177; 23.24</td><td align="center" valign="middle" >107.82 &#177; 22.97</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >LMR</td><td align="center" valign="middle" >3.84 &#177; 0.90</td><td align="center" valign="middle" >4.91 &#177; 1.45</td><td align="center" valign="middle" >0.002</td></tr></tbody></table></table-wrap><p>表1. 术前炎性指标与喉癌复发的关联</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Association between preoperative single inflammatory index and clinical feature</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >中性粒细胞(&#215;10<sup>9</sup>/L)</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >淋巴细胞(&#215;10<sup>9</sup>/L)</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >单核细胞(&#215;10<sup>9</sup>/L)</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >血小板(&#215;10<sup>9</sup>/L)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.03</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.423</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.285</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.181</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >4.26 &#177; 1.41</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.01 &#177; 0.49</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >220.40 &#177; 34.97</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >3.14 &#177; 0.68</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.87 &#177; 0.31</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.42 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >203.13 &#177; 24.18</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >饮酒史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.894</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.891</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.618</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.358</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >4.14 &#177; 1.28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.99 &#177; 0.42</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >220.96 &#177; 33.89</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >4.09 &#177; 1.64</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.01 &#177; 0.59</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.45 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >212.52 &#177; 35.09</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.405</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.233</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.765</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.215</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >4.06 &#177; 1.28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.96 &#177; 0.43</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >217.01 &#177; 34.14</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >5.06 &#177; 2.39</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.47 &#177; 0.81</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.44 &#177; 0.15</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >236.8 &#177; 33.06</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.138</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.847</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.139</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >4.24 &#177; 1.53</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.02 &#177; 0.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.46 &#177; 0.13</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >222 &#177; 33.29</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >3.81 &#177; 0.82</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.93 &#177; 0.41</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.16</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >208.11 &#177; 35.69</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.216</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.226</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.502</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.868</td></tr><tr><td align="center" valign="middle" >高分化</td><td align="center" valign="middle" >4.15 &#177; 1.41</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.03 &#177; 0.47</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >218.09 &#177; 36.15</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >3.87 &#177; 1.41</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.04 &#177; 0.53</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.45 &#177; 0.15</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >220.56 &#177; 34.44</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >4.77 &#177; 1.16</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.75 &#177; 0.28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.51 &#177; 0.12</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >213.8 &#177; 29.44</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >肿瘤部位</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >0.06</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >0.838</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >0.636</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >0.077</th></tr></thead><tr><td align="center" valign="middle" >声门区</td><td align="center" valign="middle" >3.89 &#177; 1.29</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.02 &#177; 0.46</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.45 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >213.04 &#177; 32.04</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >声门上区</td><td align="center" valign="middle" >4.57 &#177; 1.65</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.96 &#177; 0.47</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.51 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >226.54 &#177; 34.13</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >声门下区</td><td align="center" valign="middle" >3.66 &#177; 0.97</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.83 &#177; 0.24</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.45 &#177; 0.18</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >208.33 &#177; 25.58</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >跨声门区</td><td align="center" valign="middle" >5.36 &#177; 0.59</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.14 &#177; 0.81</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.48 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >250.8 &#177; 44.87</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.254</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.154</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.304</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.242</td></tr><tr><td align="center" valign="middle" >T1~T2</td><td align="center" valign="middle" >4.01 &#177; 1.43</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.05 &#177; 0.45</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.15</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >215.49 &#177; 32.76</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T3~T4</td><td align="center" valign="middle" >4.44 &#177; 1.25</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.86 &#177; 0.53</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.43 &#177; 0.12</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >226.32 &#177; 37.65</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.076</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.305</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.402</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.073</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >4.72 &#177; 1.4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.88 &#177; 0.56</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.49 &#177; 0.13</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >233.07 &#177; 35.78</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >3.99 &#177; 1.36</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.03 &#177; 0.46</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.46 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >214.77 &#177; 33.14</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >临床分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.089</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.212</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.925</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.052</td></tr><tr><td align="center" valign="middle" >早期</td><td align="center" valign="middle" >3.92 &#177; 1.42</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.05 &#177; 0.47</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.46 &#177; 0.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >212.69 &#177; 31.94</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >晚期</td><td align="center" valign="middle" >4.52 &#177; 1.25</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.89 &#177; 0.49</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.47 &#177; 0.13</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >229.42 &#177; 36.39</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 术前单一性炎性指标与临床特征的关联</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation between preoperative composite inflammatory index and clinical feature</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >NLR</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >PLR</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >LMR</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.078</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.657</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.343</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >2.17 &#177; 0.70</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >114.12 &#177; 25.44</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.49 &#177; 1.28</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >1.72 &#177; 0.43</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >110.02 &#177; 12.66</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.98 &#177; 2.06</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >饮酒史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.803</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.72</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.574</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >2.13 &#177; 0.65</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >114.34 &#177; 22.12</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.48 &#177; 1.32</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >2.09 &#177; 0.79</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >112.05 &#177; 29.28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.69 &#177; 1.53</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.848</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.786</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.038</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >2.11 &#177; 0.61</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >114.12 &#177; 21.69</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.45 &#177; 1.29</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >2.25 &#177; 1.54</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >107.48 &#177; 51.03</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5.77 &#177; 2.02</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.465</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.569</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.594</td></tr><tr><td align="center" valign="middle" >≥60</td><td align="center" valign="middle" >2.16 &#177; 0.75</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >114.63 &#177; 24.97</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.59 &#177; 1.44</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;60</td><td align="center" valign="middle" >2.02 &#177; 0.47</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >110.81 &#177; 22.64</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.39 &#177; 1.22</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.268</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.027</td></tr><tr><td align="center" valign="middle" >高分化</td><td align="center" valign="middle" >2.08 &#177; 0.64</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >110.99 &#177; 22.72</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.62 &#177; 1.4</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >1.93 &#177; 0.56</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >112.66 &#177; 24</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.83 &#177; 1.43</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >2.77 &#177; 0.84</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >125.09 &#177; 29.16</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.5 &#177; 0.42</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤部位</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.053</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.332</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.391</td></tr><tr><td align="center" valign="middle" >声门区</td><td align="center" valign="middle" >1.98 &#177; 0.6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >110.15 &#177; 21.8</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.73 &#177; 1.49</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >声门上区</td><td align="center" valign="middle" >2.39 &#177; 0.88</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >120.53 &#177; 28.88</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.02 &#177; 1.11</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >声门下区</th><th align="center" valign="middle" >1.97 &#177; 0.31</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >113.54 &#177; 5.39</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >4.39 &#177; 1.07</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >跨声门区</td><td align="center" valign="middle" >2.69 &#177; 0.64</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >125.91 &#177; 35.61</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.52 &#177; 0.88</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.595</td></tr><tr><td align="center" valign="middle" >T1~T2</td><td align="center" valign="middle" >1.98 &#177; 0.57</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >108.82 &#177; 21.13</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.59 &#177; 1.45</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T3~T4</td><td align="center" valign="middle" >2.49 &#177; 0.85</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >126.61 &#177; 27.9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.39 &#177; 1.18</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >2.58 &#177; 0.82</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >129.96 &#177; 29.72</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.88 &#177; 0.81</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >2.01 &#177; 0.61</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >109.57 &#177; 21.14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.71 &#177; 1.45</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >临床分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.148</td></tr><tr><td align="center" valign="middle" >早期</td><td align="center" valign="middle" >1.94 &#177; 0.58</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >107.64 &#177; 21.69</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.72 &#177; 1.47</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >晚期</td><td align="center" valign="middle" >2.46 &#177; 0.77</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >125.16 &#177; 25.28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.21 &#177; 1.12</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. 术前复合性炎性指标与临床特征的关联</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>许多研究显示肿瘤大小、组织学分级或淋巴结转移等组织病理学特征与癌症的预后相关，由于个体的差异性，先天免疫反应以及疾病的遗传驱动因素，仅凭借肿瘤特征来评估恶性肿瘤患者的预后并不满足目前临床诊疗需要 [<xref ref-type="bibr" rid="hanspub.40723-ref9">9</xref>]。近年来，随着人们对肿瘤发生发展规律认识的不断深化及对其分子及免疫机制的探索的不断拓展，越来越多的证据表明，全身炎症反应与肿瘤进展、侵袭密切相关。在癌症起始阶段，非可控炎症导致细胞局部微环境改变，从而导致细胞代谢调节紊乱，进一步引起基因层面突变从而导致癌症的发生、发展。在癌症发生后，免疫细胞由于肿瘤抗原诱导的免疫反应而迁移至肿瘤所处部位，同样癌细胞募集免疫调节细胞以诱导免疫抑制网络，从而逃避宿主免疫。这种相互作用反映了肿瘤的微​​环境和全身炎症状态，炎症及免疫状态失衡进一步影响癌症的发生发展。相较于肿瘤的组织病理学特征，炎症相关细胞计数在不需要手术等特殊治疗前就可以很容易地通过全血细胞(CBC)计数获得，且通过抽血获取CBC数据成本低，可以定期进行，对患者的风险小。</p><p>自1863年Virchow提出癌症与慢性炎症存在关联的假设，越来越多的证据表明，炎症参与了肿瘤发生和发展，在一个富含炎症细胞、生长因子等的炎症微环境中，肿瘤更容易发生发展 [<xref ref-type="bibr" rid="hanspub.40723-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref5">5</xref>]。2010年Roxburgh和McMillan发表了一篇关于全身炎症反应在预测手术治疗后癌症患者生存率中作用的全面综述。他们纳入了80项研究，在这些研究中生化或血液学指标，如C反应蛋白、白细胞、中性粒细胞和血小板计数，可以预测癌症的存活率 [<xref ref-type="bibr" rid="hanspub.40723-ref7">7</xref>]。目前除了研究使用炎症反应的单一标志物，如CRP、白蛋白、中性粒细胞、淋巴细胞和血小板计数。研究基于全身炎症反应的联合评分系统的预后价值的研究数量明显增加，如NLR、PLR、LMR、GPS/mGPS等，虽然这些研究报告了全身炎症反应和存活率之间的显著关系，但是对于单个或联合的标记物使用了不同的阈值，导致所报道的影响的大小有很大的差异 [<xref ref-type="bibr" rid="hanspub.40723-ref6">6</xref>]。最近的一篇关于炎性指标与癌症发生发展关系的meta分析中 [<xref ref-type="bibr" rid="hanspub.40723-ref6">6</xref>]，纳入了244篇文章，对全身炎症反应综合评分(NLR、PLR、LMR、GPS和MGPS)在原发性可手术癌症患者中的预后价值进行了评估。结果显示，NLR、PLR、LMR与多种肿瘤的总生存率和疾病特异性生存率显著相关。</p><p>在本研究中，单一的炎性指标中仅淋巴细胞与喉癌复发上存在统计学意义，复发组淋巴细胞平均值较未复发组要低，中性粒细胞、血小板数值比未复发组要高。这与Kara, M.等 [<xref ref-type="bibr" rid="hanspub.40723-ref10">10</xref>] 人研究得出了相似的结果，单一的炎性指标与喉癌患者临床特征间无明显统计学差异，他们还发现，喉癌患者治疗前外周血中PLR可作为判断生存时间的预后指标，NLR可作为判断局部复发的预后指标。Chiyao Hsueh等 [<xref ref-type="bibr" rid="hanspub.40723-ref9">9</xref>] 关于979例喉癌患者的研究中也发现，中性粒细胞、血小板和单核细胞的绝对数在术前升高，淋巴细胞的绝对数在术前下降，术前淋巴细胞、NLR、PLR和LMR与肿瘤进展、无病生存期和肿瘤特异性生存期显著相关，这些血液学参数对喉癌患者预后有着独立的预测价值。</p><p>单一的炎性指标往往受到许多因素的影响，而联合性炎症指标似乎在评估肿瘤的预后上更有价值。这可能与单一的炎性指标在机体内复杂的作用有关。中性粒细胞对癌症的发生、发展有着抑制和促进的双重作用 [<xref ref-type="bibr" rid="hanspub.40723-ref9">9</xref>]。中性粒细胞可以通过直接和抗体介导的肿瘤细胞毒性以及诱导T细胞和树突状细胞等免疫细胞的激活而发挥抗肿瘤作用。但另一方面，中性粒细胞可被肿瘤细胞衍生的细胞因子激活，被激活的中性粒细胞通过分泌促血管生成因子包括MMP9和VEGF来促进肿瘤生长和血管生成 [<xref ref-type="bibr" rid="hanspub.40723-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref12">12</xref>]。淋巴细胞与中性粒细胞不同，它在机体防御对抗肿瘤中起着关键性的作用。淋巴细胞介导的体液免疫与细胞免疫能抑制肿瘤细胞的增殖和迁移并诱导肿瘤细胞毒性死亡。NLR在多种癌症中显示与生存率相关。血小板被认为与癌症进展有关，它们通过释放相关生长因子，促进肿瘤在转移部位的血管生成和生长，使肿瘤生长和转移扩散 [<xref ref-type="bibr" rid="hanspub.40723-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref17">17</xref>]。单核细胞通过帮助肿瘤细胞逃避免疫，其演变成的巨噬细胞在肿瘤微环境中能促进血管生成及肿瘤转移 [<xref ref-type="bibr" rid="hanspub.40723-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40723-ref19">19</xref>]。</p><p>在本研究中，NLR、PLR和LMR均与喉癌的复发存在关联，结果显示NLR、PLR升高以及LMR降低可促进喉癌复发，在其他的研究中也有相似的结果 [<xref ref-type="bibr" rid="hanspub.40723-ref20">20</xref>]。Zhong, B.等人 [<xref ref-type="bibr" rid="hanspub.40723-ref21">21</xref>] 研究显示随着术后PLR的增加，T3~T4喉癌患者的生存率和复发率呈明显上升趋势。PLR的变化对喉癌的预后有较强的预测意义。不仅在手术治疗后能预测生存率，在接受放疗治疗的喉癌中也显示循环中的中性粒细胞计数和NLR可能是喉癌患者的独立预后指标 [<xref ref-type="bibr" rid="hanspub.40723-ref22">22</xref>]。炎性指标在癌前病变及癌症中也存在差异 [<xref ref-type="bibr" rid="hanspub.40723-ref23">23</xref>]，有文献报道，NLR在喉癌、癌前病变及喉良性病变中表达存在差异 [<xref ref-type="bibr" rid="hanspub.40723-ref24">24</xref>]，但还需要进一步大样本研究去证实。预防疾病的发生、提高疾病的生存率对于疾病的治疗至关重要，特别是对于肿瘤患者，寻找提高早期诊断和判断预后的方法是早防早治的关键。炎性指标方便获取，且成本低，我们的研究显示淋巴细胞、NLR、PLR、LMR与喉癌的复发相关，且与患者较差的临床特征相关，应将这些炎性指标常规用于术前检测及术后随访复查。但因为目前研究没有统一的度量标准，今后还需要去制定统一的评估标准及进一步的前瞻性研究验证。</p><p>本研究存在一些局限性。首先，这项研究为回顾性研究，需要进一步进行前瞻性研究验证。其次，研究分析了术前炎性指标的变化，但治疗后一段时间炎性指标的变化情况未进行研究，治疗后炎症指标的变化趋势是否更能预测复发风险需进一步研究。最后，研究对象为青岛大学附属医院就诊患者，可能会存在地域人口上的差异。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，术前NLR、PLR升高以及淋巴细胞、LMR降低可用于预测喉癌的复发。炎性指标应作为术前及术后常规检测项目，并且需要进一步前瞻性研究，制定统一标准用于协助临床诊疗。</p></sec><sec id="s10"><title>文章引用</title><p>唐艳珍,王得力,赵修凯,邱 杰. 术前炎性指标评估喉癌复发的临床意义The Clinical Significance of Preoperative Inflammatory Indexes in Evaluating the Recurrence of Laryngeal Carcinoma[J]. 临床医学进展, 2021, 11(02): 755-762. https://doi.org/10.12677/ACM.2021.112108</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40723-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Pan, X.L. and Lin, Y. (2020) The Correct Selection of Treatment Strategies for Laryngeal Cancer to Improve the Survival Rate and Quality of Life for Patients. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 55, 1111-1115.</mixed-citation></ref><ref id="hanspub.40723-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">陈文杰, 王斌全, 高伟, 等. 喉癌流行病学特征及影响因素分析[J]. 中国当代医药, 2015, 22(12): 43-46.</mixed-citation></ref><ref id="hanspub.40723-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">魏矿荣, 郑荣寿, 梁智恒, 等. 2014年中国喉癌发病与死亡分析[J]. 中华肿瘤杂志, 2018, 40(10): 736-743.</mixed-citation></ref><ref id="hanspub.40723-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? The Lancet, 357, 539-545.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(00)04046-0</mixed-citation></ref><ref id="hanspub.40723-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867.  
&lt;br&gt;https://doi.org/10.1038/nature01322</mixed-citation></ref><ref id="hanspub.40723-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dolan, R.D., et al. (2017) The Role of the Systemic Inflammatory Response in Predicting Outcomes in Patients with Operable Cancer: Systematic Review and Meta-Analysis. Scientific Reports, 7, Article No. 16717.  
&lt;br&gt;https://doi.org/10.1038/s41598-017-16955-5</mixed-citation></ref><ref id="hanspub.40723-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Roxburgh, C.S.D. and McMillan, D.C. (2010) Role of Systemic Inflammatory Response in Predicting Survival in Patients with Primary Operable Cancer. Future Oncology, 6, 149-163. &lt;br&gt;https://doi.org/10.2217/fon.09.136</mixed-citation></ref><ref id="hanspub.40723-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zanoni, D.K., Patel, S.G. and Shah, J.P. (2019) Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications. Current Oncology Reports, 21, 52.  
&lt;br&gt;https://doi.org/10.1007/s11912-019-0799-x</mixed-citation></ref><ref id="hanspub.40723-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hsueh, C., et al. (2017) The Prognostic Value of Preoperative Neutrophils, Platelets, Lymphocytes, Monocytes and Calculated Ratios in Patients with Laryngeal Squamous Cell Cancer. Oncotarget, 8, 60514-60527.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.16234</mixed-citation></ref><ref id="hanspub.40723-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kara, M., et al. (2017) The Pre-Treatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Red Cell Distribution Width Predict Prognosis in Patients with Laryngeal Carcinoma. European Archives of Oto-Rhino- Laryngology, 274, 535-542. &lt;br&gt;https://doi.org/10.1007/s00405-016-4250-8</mixed-citation></ref><ref id="hanspub.40723-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Dumitru, C.A., Lang, S. and Brandau, S. (2013) Modulation of Neutrophil Granulocytes in the Tumor Microenvironment: Mechanisms and Consequences for Tumor Progression. Seminars in Cancer Biology, 23, 141-148.  
&lt;br&gt;https://doi.org/10.1016/j.semcancer.2013.02.005</mixed-citation></ref><ref id="hanspub.40723-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Shacter, E. and Weitzman, S.A. (2002) Chronic Inflammation and Cancer. Oncology (Williston Park), 16, 217-226.</mixed-citation></ref><ref id="hanspub.40723-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancer-Related Inflammation. Nature, 454, 436-444.  
&lt;br&gt;https://doi.org/10.1038/nature07205</mixed-citation></ref><ref id="hanspub.40723-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bambace, N.M. and Holmes, C.E. (2011) The Platelet Contribution to Cancer Progression. Journal of Thrombosis and Haemostasis, 9, 237-249. &lt;br&gt;https://doi.org/10.1111/j.1538-7836.2010.04131.x</mixed-citation></ref><ref id="hanspub.40723-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sylman, J.L., Mitrugno, A., Tormoen, G.W., Wagner, T.H., Mallick, P. and McCarty, O.J.T. (2017) Platelet Count as a Predictor of Metastasis and Venous Thromboembolism in Patients with Cancer. Convergent Science Physical Oncology, 3, Article ID: 023001. &lt;br&gt;https://doi.org/10.1088/2057-1739/aa6c05</mixed-citation></ref><ref id="hanspub.40723-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">McCarty, O.J., Mousa, S.A., Bray, P.F. and Konstantopoulos, K. (2000) Immobilized Platelets Support Human Colon Carcinoma Cell Tethering, Rolling, and Firm Adhesion under Dynamic Flow Conditions. Blood, 96, 1789-1797.  
&lt;br&gt;https://doi.org/10.1182/blood.V96.5.1789</mixed-citation></ref><ref id="hanspub.40723-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Goubran, H.A., Burnouf, T., Radosevic, M. and El-Ekiaby, M. (2013) The Platelet-Cancer Loop. European Journal of Internal Medicine, 24, 393-400. &lt;br&gt;https://doi.org/10.1016/j.ejim.2013.01.017</mixed-citation></ref><ref id="hanspub.40723-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Y.C., Yi, Z.J., Zhou, Y., et al. (2017) Overexpression of RIP140 Suppresses the Malignant Potential of Hepatocellular Carcinoma by Inhibiting NFkappaB Mediated Alternative Polarization of Macrophages. Oncology Reports, 37, 2971-2979. &lt;br&gt;https://doi.org/10.3892/or.2017.5551</mixed-citation></ref><ref id="hanspub.40723-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">束青华, 张楠楠, 韩建波, 易永祥, 张郁峰. 淋巴细胞与单核细胞比值在肝细胞癌患者中的预后价值分析[J]. 中国普通外科杂志, 2020, 29(7): 867-876.</mixed-citation></ref><ref id="hanspub.40723-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L., et al. (2018) Survival and Prognostic Analysis of Preoperative Inflammatory Markers in Patients Undergoing Surgical Resection for Laryngeal Squamous Cell Carcinoma. BMC Cancer, 18, 816.  
&lt;br&gt;https://doi.org/10.1186/s12885-018-4730-x</mixed-citation></ref><ref id="hanspub.40723-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zhong, B., et al. (2018) May the Change of Platelet to Lymphocyte Ratio Be a Prognostic Factor for T3-T4 Laryngeal Squamous Cell Carcinoma: A Retrospective Study. PLoS ONE, 13, e0210033.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0210033</mixed-citation></ref><ref id="hanspub.40723-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sumner, W.A., et al. (2017) Survival Impact of Pre-Treatment Neutrophils on Oropharyngeal and Laryngeal Cancer Patients Undergoing Definitive Radiotherapy. Journal of Translational Medicine, 15, 168.  
&lt;br&gt;https://doi.org/10.1186/s12967-017-1268-7</mixed-citation></ref><ref id="hanspub.40723-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Seckin, K.D., Karsli, M.F., Yucel, B., Bestel, M., Yildirim, D., Canaz, E., et al. (2016) The Utility of Tumor Markers and Neutrophil Lymphocyte Ratio in Patients with an Intraoperative Diagnosis of Mucinous Borderline Ovarian Tumor. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 196, 60-63.  
&lt;br&gt;https://doi.org/10.1016/j.ejogrb.2015.10.025</mixed-citation></ref><ref id="hanspub.40723-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Kum, R.O., et al. (2014) Elevated Neutrophil-to-Lymphocyte Ratio in Squamous Cell Carcinoma of Larynx Compared to Benign and Precancerous Laryngeal Lesions. Asian Pacific Journal of Cancer Prevention, 15, 7351-7355.  
&lt;br&gt;https://doi.org/10.7314/APJCP.2014.15.17.7351</mixed-citation></ref></ref-list></back></article>